297 related articles for article (PubMed ID: 29108666)
21. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
22. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
23. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
Beadnall HN; Gill AJ; Riminton S; Barnett MH
Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
[No Abstract] [Full Text] [Related]
24. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
Grebenciucova E; Reder AT; Bernard JT
Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
[TBL] [Abstract][Full Text] [Related]
25. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
[No Abstract] [Full Text] [Related]
26. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
27. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
28. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A
Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454
[TBL] [Abstract][Full Text] [Related]
29. Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
Zanetta C; Filippi M; Moiola L
Neurol Sci; 2021 May; 42(Suppl 1):9-13. PubMed ID: 33904006
[TBL] [Abstract][Full Text] [Related]
30. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Zięba N; Gębka-Kępińska B; Sowa P
Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
[TBL] [Abstract][Full Text] [Related]
31. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
32. Folliculotropic Mycosis Fungoides as a Posttransplant Lymphoproliferative Disorder.
Spence-Shishido A; Streicher JL; George RP; Parker SR; Lawley LP
Pediatrics; 2015 Sep; 136(3):e701-5. PubMed ID: 26283779
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
35. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
36. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
[No Abstract] [Full Text] [Related]
37. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
38. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
Benedetti MD; Marangi A; Bozzetti S; Gobbin F; Turatti M; Pea M; Gajofatto A; Mocella S
Mult Scler Relat Disord; 2018 Jul; 23():24-26. PubMed ID: 29734135
[TBL] [Abstract][Full Text] [Related]
39. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P
Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512
[TBL] [Abstract][Full Text] [Related]
40. Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient.
Breville G; Lascano AM; Merkler D; Roth S; Lalive PH
Mult Scler Relat Disord; 2019 Sep; 34():63-65. PubMed ID: 31229736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
